Non-familial restrictive cardiomyopathy
MONDO:0016345259 clinical trials for this condition and its sub-types, 0 tagged with Non-familial restrictive cardiomyopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Non-familial restrictive cardiomyopathy
-
AL amyloidosis 93 trials · 99 incl. sub-types
2 sub-types
- Primary systemic amyloidosis 22 trials
- Primary localized amyloidosis 0 trials
-
Wild type ATTR amyloidosis 95 trials
-
Hypereosinophilic syndrome 19 trials · 49 incl. sub-types
8 sub-types
- Pulmonary eosinophilia 30 trials Sub-types →
- Idiopathic hypereosinophilic syndrome 1 trial Sub-types →
- Secondary hypereosinophilic syndrome 0 trials · 1 incl. sub-types Sub-types →
- Disseminated eosinophilic collagen disease 0 trials
- Eosinophilia-myalgia syndrome 0 trials
- Episodic angioedema with eosinophilia 0 trials
- Hypereosinophilia of undetermined significance 0 trials
- Primary hypereosinophilic syndrome 0 trials
-
Cardiac sarcoidosis 19 trials
-
AA amyloidosis 2 trials
-
Loeffler endocarditis 0 trials
-
Tropical endomyocardial fibrosis 0 trials
Most studied deeper sub-types
-
Heart scan study sees if new drug clears sticky proteins
Disease control CompletedThis study looks at whether the drug eplontersen can reduce abnormal protein buildup in the heart for people with a condition called ATTR-CM. About 150 participants from a larger trial will get heart scans after 140 weeks of treatment. The goal is to see if the drug helps clear t…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control CompletedThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
10-Year study tracks heart drug vyndamax in Real-World patients
Disease control CompletedThis study is monitoring 110 adults in Korea who are taking Vyndamax (tafamidis) for a rare heart condition called ATTR-CM. The goal is to track side effects and see how well the drug works over 10 years in everyday medical practice. Researchers will check heart function and symp…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection breathe life into COPD treatment?
Disease control CompletedThis study looks at whether dupilumab, an injectable medication, can improve lung function and reduce symptoms in adults with COPD who have a specific type of inflammation. The researchers are reviewing medical records from patients who received dupilumab as part of routine care,…
Sponsor: Azienda Ospedaliera di Perugia • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental drug shows promise for rare amyloidosis
Disease control CompletedThis phase 2 study tested a drug called belantamab mafodotin in 35 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Participants had already tried other treatments without success. The goal was to see if the drug could reduce or eliminate tho…
Phase 2 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail targets rare protein disease in early trial
Disease control CompletedThis early-phase trial tested a combination of three drugs—daratumumab, ixazomib, and dexamethasone—in 21 people with AL amyloidosis, a rare disease where abnormal protein builds up in organs. The main goal was to find the safest dose and check for side effects. Researchers also …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for kids with rare blood disorder: drug may cut flares and steroid use
Disease control CompletedThis study tested the drug mepolizumab in 16 children aged 6 to 17 with hypereosinophilic syndrome (HES), a rare condition causing too many eosinophils (a type of white blood cell). The goal was to see if mepolizumab could reduce disease flares and lower the need for steroids ove…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare heart disease: drug shows promise in japanese trial
Disease control CompletedThis study tested a drug called ALXN2060 (acoramidis) in 25 Japanese patients with a rare heart condition called ATTR-CM, which causes heart failure. The drug is taken as a tablet twice daily. Researchers measured how far patients could walk in 6 minutes and tracked heart-related…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a new drug ease nerve pain in rare heart disease?
Disease control CompletedThis study tested the drug patisiran in 10 adults with a rare condition called ATTR amyloidosis that causes nerve damage. Participants received an IV infusion every 21 days for 24 months. Researchers measured changes in nerve function, autonomic symptoms, and quality of life to s…
Early phase 1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Heart drug vyndaqel tracked in Real-World study
Disease control CompletedThis study looked at how safe and effective Vyndaqel is for people with a rare heart condition called transthyretin amyloid cardiomyopathy. Over 1,200 patients in Japan were followed while taking the drug in regular medical practice. The main goal was to track side effects and su…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Real-World data shows High-Dose tafamidis may slow nerve damage in ATTR-CM patients
Disease control CompletedThis study looked at medical records of 50 people with a rare heart condition called ATTR-CM to see if high-dose tafamidis (Vyndamax) slows nerve damage. Researchers compared how fast nerve problems got worse before and after starting the drug. The goal was to see if the medicati…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New COPD treatment cuts hospital returns in severe cases
Disease control CompletedThis study tested whether a drug called mepolizumab, given after a severe COPD flare-up that required hospital care, could prevent future hospital stays or death. It involved 238 adults with eosinophilic COPD (a type with high levels of certain white blood cells). Participants re…
Phase 2/3 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug patisiran aims to help hearts stiffened by rare protein disease
Disease control CompletedThis phase 3 trial tested the drug patisiran in 360 people with ATTR amyloidosis with cardiomyopathy, a condition where abnormal protein builds up in the heart, making it stiff and weak. Participants received either patisiran or a placebo intravenously. The study measured how far…
Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New asthma drug shows promise in real-world greek study
Disease control CompletedThis study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearabl…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Asthma drug benralizumab put to the test in everyday life
Disease control CompletedThis study looked at how well benralizumab (Fasenra) works for people with severe eosinophilic asthma in real-world clinics across the Gulf, Latin America, and India. Researchers tracked 291 patients to see if their asthma control improved over time using a standard questionnaire…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Air purifiers put to the test for COPD relief
Disease control CompletedThis study looked at whether using a HEPA air purifier at home can improve lung health in adults with a type of COPD called eosinophilic COPD. 178 people took part, with half getting real purifiers and half getting fake ones. The main goal was to see if the purifiers helped with …
Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental drug shows promise for stiff heart disease
Disease control CompletedThis study tested an experimental drug called NNC6019-0001 in 105 people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart, causing heart failure. Participants received either the drug or a placebo by infusion every 4 weeks for a…
Phase 2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene editing breakthrough? CRISPR therapy targets rare amyloidosis
Disease control CompletedThis early-stage trial tests NTLA-2001, a CRISPR-based gene editing therapy, in 72 adults with hereditary ATTR amyloidosis—a condition where abnormal protein builds up in nerves or the heart. The treatment aims to turn off the faulty gene to reduce protein levels. The study focus…
Phase 1 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Real-world study confirms mepolizumab cuts asthma attacks and steroid use
Disease control CompletedThis study followed 106 adults with severe eosinophilic asthma in Poland who received mepolizumab injections every 4 weeks for at least a year. Researchers tracked asthma attacks and the need for oral steroids before and during treatment. The goal was to see if the drug helps con…
Sponsor: Medical University of Lodz • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could dupilumab help Hard-to-Treat asthma patients?
Disease control CompletedThis study looked at whether dupilumab, a drug that blocks certain immune signals, can reduce signs of autoimmunity in the airways of people with severe asthma. 30 patients were followed for 4 months. The goal was to see if this approach could help those who don't get better with…
Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Drug dasatinib tested for rare blood cancers
Disease control CompletedThis study tested the drug dasatinib in 68 adults with several types of blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control the disease and to check its safety. Participants took dasati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising combo therapy targets rare protein disease in major trial
Disease control CompletedThis study tested whether adding daratumumab to standard chemotherapy (CyBorD) helps people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 416 adults took part. The goal was to see if the combination leads to better blood res…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Real-World study checks tafamidis for rare heart disease in korea
Disease control CompletedThis study looked at how well the drug tafamidis 61mg works for Korean patients with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers tracked 13 patients who were already prescribed the drug in real-world clinics. They measured changes in …
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Tiny study checks heart drug safety in india
Disease control CompletedThis study looked at the safety of a drug called Tafamidis (brand name VyndaMx) in 6 people in India with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). In ATTR-CM, faulty proteins build up in the heart and make it harder to pump blood. Researchers …
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Nasal spray shows promise for tough asthma in early trial
Disease control CompletedThis study tested an experimental nasal spray called AD17002 in 40 adults with poorly controlled moderate-to-severe eosinophilic asthma. Participants self-administered the spray twice a week for six weeks. The goal was to see if it could improve lung function and reduce the need …
Phase 1/2 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:35 UTC
-
Experimental antibody shows promise for rare amyloid disease
Disease control CompletedThis phase II trial tested the drug isatuximab in 43 patients with AL amyloidosis that had come back or stopped responding to treatment. Isatuximab is a monoclonal antibody that may help stop abnormal protein buildup. The study measured how well the drug reduced disease markers a…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
A new scan aims to watch amyloid deposits in the body over time
Diagnosis CompletedThis study tests whether a special PET/CT scan can measure changes in amyloid deposits in organs of people with systemic amyloidosis. Participants receive an injection of a radiolabeled peptide that binds to amyloid, then undergo imaging at different times. Researchers compare th…
Phase 2 • Sponsor: University of Tennessee Graduate School of Medicine • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New PET tracer could spot rare heart disease without a biopsy
Diagnosis CompletedThis completed Phase 3 study tested whether a radioactive tracer called [18F]Florbetaben, used in PET scans, can accurately diagnose cardiac AL amyloidosis—a condition where abnormal proteins build up in the heart. 244 adults with suspected cardiac amyloidosis received a single P…
Phase 3 • Sponsor: Lantheus Germany GmbH • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Stress echo could unmask hidden heart valve disease in amyloidosis patients
Diagnosis CompletedThis study looked at 15 patients with a rare heart condition called wild-type transthyretin amyloid cardiomyopathy (ATTRwt) who also had signs of aortic stenosis. Researchers used dobutamine stress echocardiography—a test that uses a drug to make the heart pump harder while imagi…
Sponsor: Steen Hvitfeldt Poulsen • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Heart amyloid spotted by new PET tracer in pilot study
Diagnosis CompletedThis pilot study tested whether a radioactive tracer called F-18 florbetapir (Amyvid) can detect amyloid protein buildup in the heart using a PET scan. Researchers enrolled 23 people with known cardiac amyloidosis and a control group without the condition. The goal was to see if …
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Heart screening study reveals hidden amyloidosis in minorities
Diagnosis CompletedThis study screened 646 elderly Black and Hispanic patients with heart failure to find out how many have cardiac amyloidosis, a condition where abnormal proteins build up in the heart. Researchers used a special heart scan and blood tests to detect the disease. The goal was to le…
Sponsor: Mathew S. Maurer, MD • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New PET tracer could sharpen amyloidosis diagnosis
Diagnosis CompletedThis phase 2 trial tested a radioactive tracer called 124I-AT-01 to see how well it can measure amyloid buildup in organs like the heart, kidneys, liver, and spleen using PET/CT scans. 33 adults with systemic amyloidosis received the tracer twice, six weeks apart. The goal was to…
Phase 2 • Sponsor: Attralus, Inc. • Aim: Diagnosis
Last updated Jun 26, 2026 13:34 UTC
-
Could ditching Beta-Blockers boost heart Patients' exercise?
Symptom relief CompletedThis study looks at whether older adults with a heart condition called cardiac amyloidosis feel better and can exercise more when they stop taking beta-blockers. Twenty participants will each go through two periods: one on their beta-blocker and one off it. Researchers will measu…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Could a diabetes drug ease heart failure in rare amyloid disease?
Symptom relief CompletedThis study tested the drug dapagliflozin (a diabetes medicine) in 50 adults with heart failure due to amyloid cardiomyopathy, a rare condition where abnormal proteins stiffen the heart. Researchers measured changes in quality of life, walking distance, and heart stress markers ov…
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Heart scans reveal hidden protein buildup in rare disease
Knowledge-focused CompletedThis study uses MRI scans to measure amyloid protein buildup in the hearts of up to 150 people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Participants are already enrolled in a larger treatment trial. The goal is to see how amyloid levels change over time, not …
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Wrist MRI may spot hidden amyloid clumps without needles
Knowledge-focused CompletedThis study tested whether a special MRI scan of the wrist can detect amyloid deposits in people with systemic amyloidosis, a condition where abnormal proteins build up in organs. Researchers enrolled 128 adults, including patients with cardiac amyloidosis and healthy volunteers. …
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
Knowledge-focused CompletedThis study looks at how mepolizumab (Nucala), a treatment for severe eosinophilic asthma, impacts emotions and mental well-being in patients and their partners. Researchers will track changes in feelings like anxiety, depression, and stress using questionnaires and interviews. Th…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Heart imaging may reveal hidden clues in rare heart disease
Knowledge-focused CompletedThis study uses advanced heart imaging to understand how blood flows inside the heart in people with cardiac amyloidosis, a condition where abnormal proteins build up in heart tissue. Researchers will compare these images with those from healthy volunteers to find unique patterns…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
Knowledge-focused CompletedThis study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Hidden nerve damage found in heart disease patients?
Knowledge-focused CompletedThis study checked how often nerve damage (neuropathy) occurs in people with a rare heart condition called wild-type TTR cardiac amyloidosis. Researchers examined 65 patients using interviews, physical exams, and nerve tests (electromyograms). The goal was to find out if nerve pr…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists seek clues to personalize AL amyloidosis treatment
Knowledge-focused CompletedThis completed study involved 250 adults with AL amyloidosis, a rare disease where abnormal proteins damage organs. Researchers analyzed patient samples and data to find biological markers that predict how well someone will respond to initial treatments. The goal is to help docto…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Blood cell study may personalize asthma and sinusitis treatment
Knowledge-focused CompletedThis study looked at different types of immune cells (eosinophils) in the blood of people with asthma, chronic sinusitis with nasal polyps, or both, compared to healthy volunteers. The goal was to find patterns that could help doctors choose the best targeted therapy for each pat…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Could your lifetime workout routine protect your heart?
Knowledge-focused CompletedThis study looked at whether being physically active over a lifetime is linked to developing a rare heart disease called wild-type transthyretin amyloid cardiomyopathy. Researchers compared the exercise histories of 180 people over age 60, including those with the disease, those …
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Heart scans may predict survival in rare amyloid disease
Knowledge-focused CompletedThis study looked at 30 people newly diagnosed with cardiac AL amyloidosis, a rare disease where abnormal proteins damage the heart. Researchers used advanced MRI, echocardiogram, and PET scans to see if these images could predict survival and show how well chemotherapy works. Th…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Asthma Drug's gene secrets revealed in small study
Knowledge-focused CompletedThis study looked at how the asthma drug mepolizumab affects gene activity in adults with severe eosinophilic asthma. Researchers took blood samples from 20 participants before and after 12 weeks of treatment to see which genes changed. The goal was to understand how the drug wor…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Protein clues could spot rare disease years early
Knowledge-focused CompletedThis study followed 37 people with a genetic risk for hereditary ATTR amyloidosis over five years. Researchers measured levels of misfolded proteins in the blood to see if they could detect the earliest signs of the disease. The goal is to develop a way to catch the condition bef…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New tool aims to give voice to heart sarcoidosis patients
Knowledge-focused CompletedThis study aimed to create and test a new questionnaire called CARD-SARC that measures how cardiac sarcoidosis affects patients' daily lives and well-being. Researchers worked with 130 adults diagnosed with cardiac sarcoidosis at two NHS specialist centres. The goal was to develo…
Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Tiny heart monitor could unlock secrets of deadly rhythms in amyloidosis
Knowledge-focused CompletedThis completed study looked at 110 people with cardiac amyloidosis, a condition where protein deposits build up in the heart. Researchers implanted a small device under the skin to continuously monitor heart rhythms for up to several years. The goal was to learn more about when a…
Sponsor: Marianna Fontana • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New clues to spot a rare blood disorder
Knowledge-focused CompletedThis study looked for new biological markers to help diagnose hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause damage. Researchers compared blood samples from 41 people with HES, those with other causes of high eosin…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Asthma Drug's hidden effects revealed in small study
Knowledge-focused CompletedThis study looked at how mepolizumab, a biologic drug, changes inflammation in people with severe eosinophilic asthma. Researchers measured immune and metabolic markers in the nose, lungs, and blood of 15 adults. The goal was to better understand the drug's full impact beyond jus…
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC